Danish drugmaker Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company ...
By Siddhi Mahatole Sept 17 (Reuters) - Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal ...
Novo Nordisk (NVO) signed a strategic collaboration and license agreement with Orbis Medicines to develop oral macrocycle therapeutics for cardiometabolic diseases, Orbis said Thu ...
Novo Nordisk A/S agreed to work with Orbis Medicines ApS on next-generation pills for heart and metabolic diseases in a ...
Novo Nordisk (OVO) teams up with Orbis Medicine to develop oral cardiometabolic treatments—in a deal worth up to $1.4B. Read ...
Deal economics for Orbis include >$1.4B upfront and milestones, tiered royalties, and a strategic Novo equity investment, ...
Novo Nordisk signs a deal worth up to $1.4bn with Orbis Medicines to develop oral drugs for cardiometabolic diseases.
Novo Nordisk (NVO) stock is in focus after signing a $1.4B deal with Orbis Medicines to develop oral drugs for ...
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement ...
Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...
Peptide drugs, such as the metabolic medicines Mounjaro and Zepbound from Eli Lilly, must be administered as injections. But the biotech industry has been pursuing ways to make peptides into pills, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results